ClinicalTrials.Veeva

Menu
T

Toledo Institute of Clinical Research Inc. | Toledo, OH

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Remibrutinib
Dupilumab
SAR440340
LOU064
SAR443765
Verekitug
UPB-101

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 11 total trials

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

The purpose of this trial is:1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 year...

Enrolling
Chronic Spontaneous Urticaria
Drug: placebo
Drug: LOU064 (blinded)

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling
Chronic Inducible Urticaria
Drug: Remibrutinib
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate t...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Enrolling
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: LOU064 (open label)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Enrolling
Asthma
Drug: Placebo
Drug: Lunsekimig

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Placebo
Drug: Oral EP262

Primary Objective:To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Inhaled Long-Acting Muscarinic Antagonist

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Primary Objective:Primary population (former smokers cohort):* Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of ac...

Active, not recruiting
Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: Itepekimab SAR440340

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week...

Enrolling
CDI
C.Difficile Diarrhea
Biological: Placebo
Biological: VE303

Trial sponsors

Novartis logo
Sanofi logo
E
U
V

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems